Millennium Management’s Grace Therapeutics GRCE Stock Holding History

Millennium Management’s Portfolio GRCE Stock Details GRCE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-780	Closed	-$21K	–	7344
2021 Q2	$21K	Buy	+780	New	+$19K	﹤0.01%	6428
2021 Q1	–	Sell	-783	Closed	-$12K	–	6591
2020 Q4	$12K	Buy	+783	New	+$9.05K	﹤0.01%	5141
2020 Q1	–	Sell	-803	Closed	-$94K	–	4608
2019 Q4	$94K	Buy	+803	New	+$79.3K	﹤0.01%	4038

Other funds holding GRCE

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

TSS

Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

EDRH

Edmond de Rothschild Holding Chambesy, Switzerland $6.91B AUM 19.7% 1-Year Est. Return

SIAP

Sterling Investment Advisors (Pennsylvania) Berwyn, Pennsylvania $599M AUM 28.66% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Millennium Management's GRCE Position: Q3 2021 in Review

Millennium Management sold out of Grace Therapeutics (GRCE) in Q3 2021, closing a stake of 780 shares — an estimated $21K sold.

Millennium Management first reported a position in GRCE in Q4 2019 and held it in 3 quarters. The position peaked at $94K in Q4 2019. 17 funds tracked by Wall St. Rank hold GRCE as of Q3 2021.

Millennium Management reported no remaining Grace Therapeutics position as of Q3 2021 after selling out during the quarter.
Millennium Management sold 780 Grace Therapeutics shares in Q3 2021, an estimated $21K.
Millennium Management first reported a position in Grace Therapeutics in Q4 2019 and held it in 3 quarters.
Millennium Management's Grace Therapeutics position peaked at $94K in Q4 2019.
17 funds tracked by Wall St. Rank held Grace Therapeutics as of Q3 2021.

Based on Millennium Management's 13F filing for Q3 2021, filed 15 Nov 2021.